Whither the attenuated psychosis syndrome?

Schizophrenia Bulletin

Volumn 38, Issue 6, 2012, Pages 1130-1134

  Yung, Alison R ^a   Woods, Scott W ^b   Ruhrmann, Stephan ^c   Addington, Jean ^d   Schultze Lutter, Frauke ^e   Cornblatt, Barbara A ^f,g,h   Amminger, G Paul ^a,i   Bechdolf, Andreas ^a,c   Birchwood, Max ^j   Borgwardt, Stefan ^k   Cannon, Tyrone D ^l   De Haan, Lieuwe ^m   French, Paul ^n,o   Fusar Poli, Paolo ^p   Keshavan, Matcheri ^q   Klosterkötter, Joachim ^c   Kwon, Jun Soo ^r   McGorry, Patrick D ^a   McGuire, Philip ^p   Mizuno, Masafumi ^s   Morrison, Anthony P ⁿ   Riecher Rössler, Anita ^t   Salokangas, Raimo K R ^u   Seidman, Larry J ^q   Suzuki, Michio ^v   Valmaggia, Lucia ^p   Van Der Gaag, Mark ^w   Wood, Stephen J ^j   McGlashan, Thomas H ^b   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BERN   (Switzerland)

^f ZUCKER HILLSIDE HOSPITAL   (United States)

^g FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^h DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k UNIVERSITY OF BASEL   (Switzerland)

^l YALE UNIVERSITY   (United States)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^p KING'S COLLEGE LONDON   (United Kingdom)

^q HARVARD MEDICAL SCHOOL   (United States)

^r Seoul National University College of Medicine   (South Korea)

^s TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^t UNIVERSITY OF BASEL   (Switzerland)

^u TURKU UNIVERSITY HOSPITAL   (Finland)

^v UNIVERSITY OF TOYAMA   (Japan)

^w UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; OMEGA 3 FATTY ACID; VITAMIN D;

ATTENUATED PSYCHOSIS SYNDROME; CONSENSUS; HEALTH CARE SYSTEM; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; STIGMA; SYMPTOM;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SOCIAL STIGMA; SYNDROME;

EID: 84869050892     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs108     Document Type: Review

References (46)

1. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22:353-370.
2. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high risk state: a comprehensive state of the art review. Arch Gen Psychiatry. In press.
3. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65: 28-37.
4. Yung AR, Nelson B, Stanford C, et al. Validation of prodromal criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105:10-17.
5. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69:220-229.
6. Fusar-Poli P, Bechdolf A, Taylor M, Carpenter W, Yung A, McGuire P. At risk for schizophrenic or affective psychosis? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk [published online ahead of print May 15, 2012]. Schizophr Bull. doi:10.1093/schbul/sbs060
7. Fusar-Poli P, Yung AR. Should attenuated psychosis syndrome be included in DSM-5? The debate. Lancet. 2012;379:591-592.
8. Nelson B, Yung AR. Should a risk syndrome for first episode psychosis be included in the DSM-5? Curr Opin Psychiatry. 2011;24:128-133.
9. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably atrisk, but certainly ill-advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010;120:23-37.
10. Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM. Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res. 2010;120:42-48.
11. Yung AR, Nelson B, Thompson AD, Wood SJ. Should a Risk Syndrome for Psychosis be included in the DSMV? Schizophr Res. 2010;120:7-15.
12. Woods SW, Walsh BC, Saksa JR, McGlashan TH. The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res. 2010;123:199-207.
13. Frances A. Predicting psychosis risk is pretty risky. Huffington Post. March 10, 2012. huffingtonpost.com/allen-frances/psychosis-risk-b-1289022.html. Accessed March 26, 2012.
14. Norrie J (ed). Backdown on new psychiatric diagnoses a welcome respite. The Conversation. May 17, 2012. http://theconversation. edu.au/backdown-on-new- psychiatric-diagnoses-a-welcome-respite-7092. Accessed May 18, 2012.
15. Castle DJ. Is it appropriate to treat people at high-risk of psychosis before first onset?-no. Med J Aust. 2012;196:557.
16. Carpenter WT, van Os J. Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry. 2011;168:460-463.
17. McGlashan TH, Addington J, Cannon T, et al. Recruitment and treatment practices for help-seeking prodromal patients. Schizophr Bull. 2007;33:715-726.
18. Ruhrmann S, Paruch J, Bechdolf A, et al. Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiatr Scand. 2008;117:357-368.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision ed. Washington, DC: American Psychiatric Association; 2000.
20. International Early Psychosis Association. International clinical practice guidelines for early psychosis. Br J Psychiatry. 2005;187:120-124.
21. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk (prodromal) group. Schizophr Res. 2003;60:21-32.
22. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67: 241-251.
23. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33:673-681.
24. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125:54-61.
25. Morrison AP, French P, Stewart SL, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ. 2012;344:e2233.
26. Fusar-Poli P, Borgwardt S. Predictive power of attenuated psychosis syndrome: is it really low? The case of mild cognitive impairment. Schizophr Res. 2012;135:192-193.
27. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290.
28. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975-983.
29. Hegelstad WT, Larsen TK, Auestad B, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169:374-380.
30. Klosterkötter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S. Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry. 2011;10:165-174.
31. Cornblatt BA, Carrión RE, Addington J, et al. Risk factors for psychosis: impaired social and role functioning. Schizophr Bull. In press.
32. Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol. 2005;44:181-191.
33. Green JG, McLaughlin KA, Berglund PA, et al. Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication I: associations with first onset of DSM-IV disorders. Arch Gen Psychiatry. 2010;67: 113-123.
34. Koutsouleris N, Meisenzahl EM, Davatzikos C, et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry. 2009;66:700-712.
35. Job DE, Whalley HC, Johnstone EC, Lawrie SM. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage. 2005;25:1023-1030.
36. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a crosssectional and longitudinal MRI comparison. Lancet. 2003;361:281-288.
37. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69:562-571.
38. van Tricht MJ, Nieman DH, Koelman JH, et al. Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biol Psychiatry. 2010;68:642-648.
39. Wood SJ, Berger G, Velakoulis D, et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra highrisk individuals. Schizophr Bull. 2003;29:831-843.
40. Kéri S, Kiss I, Kelemen O. Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. Mol Psychiatry. 2009;14:118-119.
41. Mössner R, Schuhmacher A, Wagner M, et al. DAOA/ G72 predicts the progression of prodromal syndromes to first episode psychosis. Eur Arch Psychiatry Clin Neurosci. 2010;260:209-215.
42. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39:964-971.
43. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863-865.
44. Wigman JT, van Nierop M, Vollebergh WA, et al. Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity-implications for diagnosis and ultra-high risk research. Schizophr Bull. 2012;38:247-257.
45. Amminger GP, Schäfer MR, Papageorgiou K, et al. Longchain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.
46. McGorry PD, Purcell R, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust. 2007;187:S40-S42.